STOCKS TELEGRAPH

Tag: AMWL

  • 3 Stocks Showing Positive Momentum: LeonaBio (LONA), American Well (AMWL), Cardiol Therapeutics (CRDL)

    3 Stocks Showing Positive Momentum: LeonaBio (LONA), American Well (AMWL), Cardiol Therapeutics (CRDL)

    The healthcare innovation landscape continues to evolve as companies pursue novel therapeutic approaches across a wide range of disease areas. Increased focus on precision medicine and targeted treatments has contributed to a growing number of assets advancing through mid- and late-stage development. Investors remain particularly attentive to programs that demonstrate both clinical differentiation and scalable commercial potential.

    LeonaBio Inc (LONA)

    LeonaBio Inc (NASDAQ: LONA) opened trading on May 07, 2026, with great promise as it jumped 4.67% to $9.86. During the day, the stock rose to $9.92 and sank to $9.51. Taking a long-term approach, LONA posted a 52-week range of $2.30-$14.21.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 32.09%. Meanwhile, its Annual Earnings per share during the time were -32.09%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 81.51%. This publicly-traded company’s shares outstanding now amount to $9.34 million, simultaneously with a float of $7.22 million. The organization now has a market capitalization of $92.62 million.

    American Well Corp (AMWL)

    American Well Corp (NYSE: AMWL) started the day on May 07, 2026, with a price increase of 8.39% at $7.75. During the day, the stock rose to $7.75 and sunk to $7.02 before settling in for the price of $7.15 at the close. Taking a long-term approach, AMWL posted a 52-week range of $3.71-$9.15.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 20.73%. Meanwhile, its Annual Earnings per share during the time was 20.73%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 43.22%. This publicly-traded company’s shares outstanding now amount to $15.01 million, simultaneously with a float of $13.39 million. The organization now has a market capitalization of $128.28 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term growth narrative by advancing therapies beyond its lead indication into broader cardiovascular markets. Through the development of next-generation assets targeting inflammation and fibrosis, the company is positioning itself to address large unmet needs in chronic heart disease.

    Market Momentum

    As of May 7, 2026, CRDL closed at $1.30, down 1.52%, with trading volume of 438,050 shares versus an average volume of 673,854 shares. The company currently carries a market capitalization of $145.184M and a beta of 0.43, reflecting relatively moderate trading volatility. Shares remain within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.41 continues to indicate substantial upside potential tied to future pipeline execution.

    Pipeline Expansion: CRD-38

    Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding treatment applicability into broader cardiovascular conditions, including heart failure. The therapy is intended to target both inflammation and fibrosis, two major biological drivers that contribute to progressive cardiac dysfunction.

    Market Opportunity

    Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating significant healthcare costs annually. Despite the availability of multiple therapies, many existing treatments do not directly address inflammatory mechanisms associated with worsening disease. If clinically validated, CRD-38 could occupy a differentiated position within this market by targeting underlying inflammatory and fibrotic pathways.

    Outlook

    As CRD-38 advances toward future clinical development, it may emerge as an important secondary value driver for Cardiol. Successful execution could diversify the company’s pipeline and significantly expand its long-term commercial opportunity.

  • Top Telehealth Stocks To Watch In January 2021

    Top Telehealth Stocks To Watch In January 2021

    Telehealth companies help people see medical professionals remotely through either the phone or video calls. And since the demand for healthcare with elements of social distancing increased during the pandemic, telemedicine services also saw an increase in demand. In the United States, when Congress passed an emergency fund of $8.3 billion, it also loosened certain rules on the use of telehealth services in the U.S. Medicare program. A lot of companies have branched into telehealth but only trade over the counter or are privately owned, except for Teladoc Health which trades on the New York Stock Exchange and has outperformed the broader market and has a market value of $12.2 billion.

    Teladoc Health Inc (NYSE: TDOC)

    Teladoc Health Inc (TDOC)‎ is one of the best telehealth stocks on Wall Street and benefited from the entire Covid pandemic ordeal since virtual healthcare became a big thing. The company gives virtual healthcare services to a wide range of stakeholders and its revenue more than doubled since then. Teladoc Health managed to close the third quarter last year with the $18.5 billion acquisition of its rival Livongo in October.

    In 2020, TDOC’s stocks began to look pricey because they had more than doubled up. It is a compelling growth story within the healthcare sector and is bound to bring in new investors over the years. It is already dubbed as a Strong Buy by 13 of the 27 analysts tracking for the S&P Global Market Intelligence.

    American Well Corp (NYSE: AMWL)

    American Well Corp (AMWL)‎ is a top-notch telemedicine company based in the United States and is rated 885 out of 1,000 which is higher than the 856 average in the industry. Amwell is part of 55 health plans at the moment and it used by nearly 36,000 employers. But the situation created by the pandemic proved to be extremely profitable for the company as seen in the visits to its platform since 2006 having been 5.6 million out of which 2.9 million of those visits happened till the middle of 2020.

    Its revenue increased by 77 per cent in the first half of 2020 by $122.3 million and its monthly visit volumes also saw a more than fourfold increase. In August, it also succeeded in securing a $100 million investment from Google, and much of that will go towards research and development and also in innovating the platform. AMWL is currently capitalized with $831.6 million in cash and investments and since September its stock is up by 70 per cent.

    M3

    M3 has been a global leader in telehealth in Japan and overseas. It is backed by Sony and initially began as a traditional operator of medical websites but it then used its acquisitions to become a provider of online medical information and telehealth. Much of M3’s revenue comes from the information it makes available to its academics, patients, and doctors. But that still makes it very profitable with a market capitalization of more than $60 billion. Its stock has been tripling over the past year as its capabilities have made it a strong stock and even the best emerging telehealth stock in the market.

    During the pandemic it gained 72 per cent for the year to date and it is predicted that with its outsized growth rate if it had been in the S&P 500, it would have been the top fifth index of the most expensive stocks.

  • 13 Trending Stocks in Health Information Services Industry

    13 Trending Stocks in Health Information Services Industry

    As investors weighed the stimulus vote of Monday against the emergence of a new ‎coronavirus strain ‎in the UK, US equities ended mixed on Tuesday.
‎

    The Senate approved the measure Monday night after months of negotiations over ‎additional fiscal ‎support. The bill funds the government through September 30 and includes ‎a new stimulus of $900 ‎billion. Also, the package includes $300 in additional federal ‎unemployment benefits and $600 in direct ‎payments. 
‎

    Some of the key players in the Health Information Services sector were:

‎‎

    NantHealth Inc. (NASDAQ:NH) shares were trading up 21.50% at $3.56 at the ‎time of writing on Tuesday.‎

    NantHealth Inc. (NASDAQ:NH) share price went from a low point around $0.92 ‎to briefly over $6.60 in past 52 weeks, though shares have since pulled back to $3.56. NH market cap ‎has remained high, hitting $427.88M at the time of writing, giving it price-to-sales ratio of more than ‎‎5.

    ‎If we look at the recent analyst rating NH, Canaccord Genuity reiterated ‎coverage on NH shares with a Buy rating and a $3.75 price target, which implies ‎room for 0.19% upside momentum this year.

    HMS Holdings Corp. (HMSY) last closed at $36.58, in a 52-week range of $18.19 ‎to $36.75. The company recently reported an agreement with Veritas Capital-backed Gainwell ‎Technologies, whereby Gainwell will acquire HMS. Analysts have a consensus price target of ‎‎$35.09.

    Teladoc Health Inc. (TDOC) stock soar by 3.15% to $206.04. The most recent ‎rating by Evercore ISI, on December 22, 2020, is at an In-line.

    American Well Corporation (NYSE:AMWL) Shares headed rising, higher as much ‎as 5.90%. The most recent rating by Stifel, on December 18, 2020, is at a Hold.

    Veeva Systems Inc. (NYSE:VEEV) rose 5.76% after gaining more than $15.61 on ‎Tuesday. Veeva reported on December 15, 2020, that Integra LifeSciences has selected Veeva Vault ‎CDMS for clinical data management. ‎

    Change Healthcare Inc. (CHNG) last closed at $18.83, in a 52-week range of ‎‎$6.18 to $18.70 following the announcement of successful introduction of its first cloud-based medical ‎tools for radiologists and other specialties along with its roadmap to help healthcare organizations ‎begin their migration of medical imaging to the cloud. Analysts have a consensus price target of ‎‎$20.39.

    GoodRx Holdings Inc. (GDRX) stock soar by 3.49% to $48.32 after announcing ‎recognition from workplace culture site Comparably for its company culture and leadership. The most ‎recent rating by RBC Capital Mkts, on November 19, 2020, is at an Outperform.

    Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) Shares headed rising, ‎higher as much as 2.15%. The company announced on December 17, 2020, that it is dedicating ‎extensive resources to ensure its clients are prepared to maximize functionality within its solutions to ‎respond to the COVID-19 pandemic. The most recent rating by Argus, on November 11, 2020, is at a ‎Buy.

    HealthEquity Inc. (NASDAQ:HQY) rose 2.27% after gaining more than $1.51 on ‎Tuesday. The company reported on December 8, 2020, that revenue for the third quarter ended ‎October 31, 2020 of $179.4 million grew 14% compared to $157.1 million for the third quarter ended ‎October 31, 2019.

    ‎Cerner Corporation (CERN) last closed at $77.38, in a 52-week range of $53.08 to ‎‎$80.90. The firm on December 16, 2020 revealed an agreement to acquire health division of Kantar. ‎Analysts have a consensus price target of $78.23.

    ‎1Life Healthcare Inc. (ONEM) stock soar by 3.97% to $43.26. The most recent ‎rating by Credit Suisse, on October 30, 2020, is at an Outperform.

    ‎So-Young International Inc. (NASDAQ:SY) Shares headed falling, lower as much ‎as -7.41%. The most recent rating by Deutsche Bank, on April 23, 2020, is at a Buy.

    ‎Schrodinger Inc. (NASDAQ:SDGR) rose 0.85% after gaining more than $0.7 on ‎Tuesday.